Co-Authors
This is a "connection" page, showing publications co-authored by William Werbel and Julie Paik.
Connection Strength
1.428
-
Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination. Arthritis Rheumatol. 2022 01; 74(1):28-32.
Score: 0.246
-
Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 10; 80(10):1365-1366.
Score: 0.241
-
Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series. Ann Intern Med. 2021 09; 174(9):1332-1334.
Score: 0.237
-
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 10; 80(10):1351-1352.
Score: 0.237
-
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 Mar 23.
Score: 0.234
-
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 Mar 19.
Score: 0.234